Long-Term Consequences of Hepatitis C Viral Clearance on the CD4 (+)‎ T Cell Lymphocyte Course in HIVHCV Coinfected Patients

الملخص EN

The long-term impact of pegylated-interferon plus ribavirin treatment outcome on CD4 T cell course in patients coinfected with human immunodeficiency virus and hepatitis C virus is largely unclear in the literature.

The aim of this study was to investigate the impact of HCV-RNA clearance by standard anti-HCV therapy on long-term CD4 cells recovery in HIV/HCV patients on successful combined antiretroviral therapy.

We retrospectively enrolled HIV/HCV-coinfected patients on HIV medications and treated for hepatitis C.

CD4 + T cell counts were registered at baseline and after hepatitis C therapy.

Multiple linear regression analysis was performed to identify independent predictors of CD4 + T cell change following the anti-HCV treatment outcome.

Of the 116 patients enrolled, 54 (46.6%) reached a sustained virological response.

During a follow-up of 24 months, the SVR group showed a mean annual increase in CD4 + T cell from baseline of 84 cells/ll at 1 year and of a further 38 cells/ll within the second year ( P = 0.01 , 0.001, resp.).

An insignificant mean increase of 77 cells/ll occurred in the non-SVR group within month 24 ( P = 0.06 ).

Variables associated with greater CD4 gains were higher nadir, lower preinterferon CD4 counts, and lower body mass index (BMI).